Ajax Therapeutics Stock

www.ajaxtherapeutics.comHealthcare / BioTech & PharmaFounded: 2019

Ajax Therapeutics is a biotechnology company that is working to develop selective and potent Type11 JAK2 inhibitors designed with the goal of treating myeloproliferative neoplasms (MPNs). Ajax Therapeutics was founded in 2019 and is headquartered in New York, New York. Through the use of computational chemistry and structural biology, researchers at Ajax Therapeutics are striving to create targeted therapies that are intended to be more effective than traditionally available JAK inhibitors.

Register To Buy and Sell Shares

For more details on financing and valuation for Ajax Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Ajax Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Ajax Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Martin Vogelbaum
Co-Founder & Chief Executive Officer
David Steensma MD
Chief Medical Officer
Alan Collis Ph.D
Senior Vice President, Head of Preclinical Development
Ross Levine MD
Craig Masse Ph.D
Senior Vice President, Discovery Research
Maria Kleppe Ph.D
Executive Director, Discovery Biology
Christine Richardson Ph.D
Senior Director, Program Management

Board Members

Amit Sinha
Goldman Sachs Asset Management
Ramy Farid Ph.D
Scott Platshon
EcoR1 Capital

Frequently Asked Questions About Ajax Therapeutics’ Stock

Can you buy Ajax Therapeutics’ stock?
Ajax Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Ajax Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Ajax Therapeutics’ stock?
Yes, you can sell stock of a private company like Ajax Therapeutics. Forge can help you sell your Ajax Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Ajax Therapeutics’ stock price?
Ajax Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Ajax Therapeutics’ private market stock price with Forge Data.
What is Ajax Therapeutics’ stock ticker symbol?
Ajax Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Ajax Therapeutics Raises $95M in Series C Financing
In a series C funding round led by Eli Lilly and Company, Vivo Capital, RA Capital Management, Point72, and more, helped raise $95 million for Ajax.
Updated on: May 25, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.